Fosun Pharma Considers Transferring RMB 3.2 Billion Compound Patents To Swiss Sellas
This article was originally published in PharmAsia News
Executive Summary
Shanghai Fosun Pharmaceutical (Group) Co. Ltd.’s owned Chongqing Fochon Pharmaceutical Co. Ltd. discussing with Switzerland-based Sellas Clinicals Holding AG plans to transfer the patents of two compounds to Sellas at an estimated €388 million ($535.91 million) by installment.